Patents
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
08/1992
08/16/1992WO1992014488A1 Structural gene of pneumococcal protein
08/12/1992EP0497922A1 Infective protein delivery system
08/12/1992EP0497875A1 2' modified oligonucleotides
08/11/1992US5138045 Polyamine conjugated oligonucleotides
08/06/1992WO1992012996A2 Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
08/06/1992WO1992012725A1 Treatment of neoplastic disease with interleukin-10
08/06/1992CA2101065A1 Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
08/06/1992CA2100553A1 Treatment of neoplastic disease with interleukin-10
08/05/1992EP0496769A1 Extracellular matrix protein adherent t cells
08/04/1992US5135916 Inhibition of complement mediated inflammatory response
07/1992
07/23/1992WO1992012242A1 Modified hepatocytes and uses therefor
07/23/1992WO1992011896A1 Drug delivery system
07/23/1992WO1992005266A3 Packaging cells
07/23/1992CA2076848A1 Modified hepatocytes and uses therefor
07/22/1992EP0451206A4 Receptor transcription-repression activity compositions and methods
07/15/1992EP0494776A1 Method of altering the metabolic state of non-dividing cells and obtained transgenic animals
07/15/1992EP0494244A1 Therapeutic ribozyme compositions and expression vectors
07/09/1992WO1992011359A1 A truncated interleukin-1 receptor gene for the treatment of arthritis
07/09/1992WO1992011355A1 Method for culturing and transforming human stem cell-containing compositions
07/09/1992WO1992011033A1 Control of gene expression by ionizing radiation
07/09/1992CA2098848A1 Truncated interleukin-1 receptor gene for the treatment of arthritis
07/08/1992EP0448704A4 Osteogenic devices
07/05/1992WO1992011874A1 Tumor susceptible non-human animals
07/05/1992CA2098827A1 Tumor susceptible non-human animals
06/1992
06/25/1992WO1992010573A1 Methods and compositions for the suppression of neu mediated transformation
06/25/1992WO1992010568A1 Dna which codes for neurotrophic activity inhibitor and use thereof
06/25/1992WO1992010563A1 Immortalized cell lines and applications thereof, especially for the production of differentiated cells
06/25/1992CA2077350A1 Dna coding for growth-inhibitory factor and use thereof
06/17/1992EP0490077A1 Antisense oligonucleotides for treatment of cancer
06/17/1992EP0489830A1 Expression of alpha-macroglobulins
06/16/1992US5122517 Antiviral combination comprising nucleoside analogs
06/15/1992WO1992010506A1 Human retrovirus receptor and dna coding therefor
06/15/1992CA2097705A1 Human retrovirus receptor and dna coding therefor
06/14/1992WO1992010564A1 Sustained and continuous production of high titers of recombinant viral vectors and transduced target cells for use in gene therapy
06/14/1992CA2098510A1 Sustained and continuous production of high titers of recombinant viral vectors and transduced target cells for use in gene therapy
06/11/1992WO1992009688A1 MICE HAVING β2 MICROGLOBULIN GENE DISRUPTION
06/11/1992WO1992002534A3 Compounds and methods for inhibiting gene expression
06/10/1992EP0489058A1 Cystic fibrosis gene
06/04/1992WO1992009616A1 Enhancement of musculature in animals
06/04/1992CA2097590A1 Enhancement of musculature in animals
06/03/1992EP0487587A1 Recombinant retroviruses delivering vector constructs to target cells
05/1992
05/26/1992US5116964 Hybrid immunoglobulins
05/14/1992WO1992008796A1 Bifunctional selectable fusion genes
05/14/1992WO1992007945A1 Cell type specific alteration of levels of gene products in neural cells
05/14/1992WO1992007943A1 Retroviral vectors useful for gene therapy
05/14/1992WO1992007939A2 Polypeptide with 46kd hmfg differentiation antigen binding specificity
05/14/1992WO1992007573A1 Genetic modification of endothelial cells
05/14/1992WO1992007572A1 Agents and methods for binding to elam-1
05/14/1992CA2095330A1 Polypeptide with kd hmfg differentiation antigen binding specificity
05/14/1992CA2095256A1 Retroviral vectors useful for gene therapy
05/14/1992CA2094911A1 Agents and methods for binding to elam-1
05/08/1992WO1992008456A2 Method of inhibiting transformation, growth and metastasis of cells in which purine metabolic enzyme activity is elevated
05/08/1992CA2095732A1 Method of inhibiting transformation, growth and metastasis of cells in which purine metabolic enzyme activity is elevated
05/06/1992WO1992007580A1 Therapeutic uses of melanin
05/06/1992EP0483219A1 Enhancement of musculature in animals
05/03/1992CA2488792A1 Antisense oligonucleotides for treatment of cancer
04/1992
04/30/1992WO1992007071A1 Methods and applications for efficient genetic suppressor elements
04/30/1992WO1992007065A1 Modified ribozymes
04/30/1992WO1992007000A1 Pharmaceutical composition for the treatment or prevention of a malignant tumor
04/30/1992WO1992006702A1 A method for transplanting cells into the brain and therapeutic uses therefor
04/30/1992CA2423998A1 Methods and applications for efficient genetic suppressor elements
04/28/1992US5109124 Nucleic acid probe linked to a label having a terminal cysteine
04/23/1992WO1992006693A1 Dna construct for providing rna therapy
04/23/1992CA2094608A1 Dna construct for providing rna therapy
04/16/1992WO1992006190A1 Transgenic model for selective targeting of gene products with a megakaryocyte promoter
04/15/1992EP0479866A1 Pestivirus nucleotide sequences and polypeptides
04/10/1992WO1992006192A1 Inhibition of viral replication
04/10/1992CA2093816A1 Inhibition of viral replication
04/08/1992EP0478708A1 Formation of triple helix complexes of double stranded dna using nucleoside oligomers
04/02/1992WO1992006180A1 Targeting viruses and cells for selective internalization by cells
04/02/1992WO1992005262A1 Methods and compositions for genetic therapy and potentiation of anti-tumor immunity
04/02/1992WO1992005254A1 Novel neurothrophic factor
04/02/1992WO1992005195A1 Viral growth inhibition
04/02/1992WO1992005184A1 A non-mitogenic competitive hgf antagonist
04/02/1992CA2092323A1 Targeting viruses and cells for selective internalization by cells
04/01/1992EP0477994A1 Parasite-derived resistance
04/01/1992EP0477290A1 Methods, compositions and devices for growing cells.
03/1992
03/26/1992WO1992005250A1 Prolonging expression of polynucleotides introduced into a cell
03/26/1992CA2092319A1 Prolonging expression of polynucleotides introduced into a cell
03/25/1992EP0476953A2 Viral targeted destruction of neoplastic cells
03/24/1992US5098823 Chromosome-specific nucleic acid probe for familial polyposis coli
03/22/1992WO1992005284A1 Compositions and methods for inhibiting growth or replication of viruses
03/22/1992WO1992005266A2 Packaging cells
03/22/1992CA2092711A1 Compositions and methods for inhibiting growth or replication of viruses
03/19/1992WO1992005273A1 Gene therapy for cystic fibrosis
03/19/1992WO1992004446A1 Cloning of chicken anaemia dna
03/19/1992WO1992004033A1 Methods for inhibiting rejection of transplanted tissue
03/19/1992CA2289222A1 Gene therapy for cystic fibrosis
03/18/1992WO1992005272A1 Method and composition for controlling proliferation of cells
03/18/1992EP0475623A1 Genetic mechanisms of tumor supression
03/18/1992EP0475178A1 Liposome for entrapping gene, liposomal preparation and process for the manufacture of the preparation
03/18/1992EP0474979A1 Heparin binding neurotrophic factor gene sequence
03/18/1992CA2091759A1 Method and composition for controlling proliferation of cells
03/05/1992WO1992003568A1 Sugar modified oligonucleotides that detect and modulate gene expression
03/05/1992WO1992003566A1 Therapeutic ribozyme compositions
03/05/1992WO1992003545A1 Flavivirus recombinant poxvirus vaccine
03/05/1992WO1992003537A1 Self-assembling replication defective hybrid virus particles
03/05/1992WO1992003456A1 Oligonucleotides for modulating the effects of cytomegalovirus infections
03/05/1992WO1992003139A1 Oligonucleotide modulation of cell adhesion
03/05/1992CA2089497A1 Self-assembling replication defective hybrid virus particles